フロリダ州におけるバセドウ病の臨床試験
フロリダ州内の拠点で、バセドウ病に関する8件の研究が参加者を募集しています。
フロリダ州内の都市
公式研究テキスト（英語）
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
- DM Clinical Research, Doral
- Floridian Clinical Research - Clinitiative, Miami
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/02更新 · NCT07722546Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
- Site-052, Doral
- Site-066, Fort Myers
- Site-019, Hialeah
- 他4件
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/10/01更新 · NCT07661056NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
- Site # 1101, Hollywood
- Site # 1112, Miami
- Site # 1109, Wesley Chapel
被験者募集中第1相
18歳〜65歳 · 全性別 · 2026/09/30更新 · NCT07305818A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
- Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park Location, Fleming Island
- The Center for Diabetes and Endocrine Care, Fort Lauderdale
- University of Florida Jacksonville College of Medicine, Jacksonville
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT07570316Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
- Site 109, Miami Lakes
- Site 115, Palm Harbor
- Site 123, Sarasota
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07682896A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- Site Number - 1024, Doral
- Site Number - 1008, Hialeah
- Site Number - 1000, Miami
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/08/25更新 · NCT07018323A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- Site Number - 1029, Clearwater
- Site Number - 1055, Jacksonville
- Site Number - 1056, Jacksonville
- 他4件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/08/25更新 · NCT06727604Study of BHV-1300 in Graves' Disease
- Site-100, Miami
被験者募集中第1相
18歳〜65歳 · 全性別 · 2026/07/31更新 · NCT06980649ClinicalTrials.govより、2026/10/03時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。